NEW YORK – Biofidelity and CellCarta said on Thursday that they have formed a strategic partnership to use Biofidelity's lung cancer assay in clinical trials worldwide.

纽约——Biofidelity和CellCarta周四表示，他们已经建立了战略合作伙伴关系，在全球临床试验中使用Biofidelity的肺癌检测方法。

Under the agreement, Canadian global research contract organization CellCarta will validate the Aspyre Lung assay first in its European and then in its US-based labs. The Montreal-based company will have non-exclusive rights to use Aspyre Lung globally in clinical trials.

根据协议，加拿大全球研究合同组织CellCarta将首先在其欧洲实验室，然后在其美国实验室验证Aspyre肺分析。这家总部位于蒙特利尔的公司将拥有在全球临床试验中使用Aspyre Lung的非排他性权利。

Financial details of the agreement were not disclosed.

该协议的财务细节未披露。

'CellCarta offers an extensive portfolio of biomarker testing services and tailored solutions for the pharmaceutical and biotech industry,' CellCarta CEO Dusty Tenney said in a statement. 'The addition of Aspyre Lung to our capabilities marks an advancement in our mission to propel precision medicine with specialized laboratory services.'.

CellCarta首席执行官达斯蒂·坦尼（DustyTenney）在一份声明中说，CellCarta为制药和生物技术行业提供了广泛的生物标志物测试服务组合和量身定制的解决方案Aspyre Lung的加入标志着我们通过专业实验室服务推进精准医学的使命取得了进步。

Aspyre Lung

is a pyrophosphorolysis-based lung cancer mutation detection assay that targets 111 mutations in 11 genes of relevance to non-small cell lung carcinoma.

是一种基于焦磷酸分解的肺癌突变检测方法，针对与非小细胞肺癌相关的11个基因中的111个突变。

A year ago, Cambridge, UK-based Biofidelity

一年前，位于英国剑桥的Biofidelity

partnered with Fidelis

与菲德利斯合作

to supply the assay to Department of Veterans Affairs medical centers and active-duty military installations across the US.

为美国退伍军人事务部医疗中心和美国各地的现役军事设施提供检测。